A0A0S2Z5U7 (A0A0S2Z5U7_HUMAN) Homo sapiens (Human)

Direct IAP-binding protein with low pI UniProtKBInterProInteractive Modelling

239 aa; Sequence (Fasta) ; 1 identical sequence: Homo sapiens: Q9NR28

Available Structures

16 Experimental Structures

DescriptionPDB IDOligo-stateRangeLigands
Cryo-EM structure of BIRC6/Smac Heteromer
Q9NR09; Q9NR28;
67-239
Assess
Cryo-EM structure of BIRC6/Smac (from local refinement 1) Heteromer
Q9NR28;
67-239
Assess
Cryo-EM structure of human BIRC6 in complex with SMAC. Heteromer
Q9NR09; Q9NR28;
56-222
ZN;
Assess
CRYSTAL STRUCTURE OF SMAC BOUND TO XIAP-BIR3 DOMAIN Heteromer
P98170; Q9NR28;
56-212
Assess
Structure of the giant inhibitor of apoptosis, BIRC6 bound to the regulator SMAC Heteromer
Q9NR09; Q9NR28;
68-217
Assess
NMR STRUCTURE OF A 9 RESIDUE PEPTIDE FROM SMAC/DIABLO COMPLEXED TO THE BIR3 DOMAIN OF XIAP Heteromer
P98170; Q9NR28;
56-64
ZN;
Assess
The BIR3 domain of cIAP1 in complex with the N terminal peptide from SMAC/DIABLO (AVPIAQ). Heteromer
Q13490; Q9NR28;
56-61
ZN;
Assess
Structure of the BIR domain of IAP-like protein 2 Heteromer
Q96P09; Q9NR28;
56-60
24×ZN;
Assess
The Structure of the BIR domain of IAP-like protein 2 Heteromer
Q96P09; Q9NR28;
56-60
23×ZN;
Assess
Structure of an ML-IAP/XIAP chimera bound to a 9mer peptide derived from Smac Heteromer
Q96CA5; Q9NR28;
56-59
ZN;
Assess
Structure and Function Analysis of Peptide Antagonists of Melanoma Inhibitor of Apoptosis (ML-IAP) Heteromer
Q96CA5; Q9NR28;
56-59
ZN;
Assess
crystal structure of human Survivin in complex with Smac/DIABLO(1-15) peptide Heteromer
O15392; Q9NR28;
56-59
ZN;
Assess
Crystal structure of human Survivin K62Y/H80W mutant in complex with Smac/DIABLO(1-15) peptide Heteromer
O15392; Q9NR28;
56-59
ZN;
Assess
Tetrameric form of Smachomo-4-mer68-224
Assess
CRYSTAL STRUCTURE OF SMAC/DIABLOhomo-2-mer67-239
Assess
Crystal structure of Smac-DIABLO (in space group P65)homo-2-mer68-239
MPD;ACT;
Assess

1 SWISS-MODEL model

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
6jx6.1.Ahomo-4-mer0.7268-224
100.00
Assess